Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Botanix Pharmaceuticals Limited ( (AU:BOT) ) has issued an announcement.
Botanix Pharmaceuticals has responded to a proposed executive order by President Trump aimed at reducing pharmaceutical costs in the US by adopting a ‘most favored nation’s policy.’ The company clarified that its product, Sofdra, is only approved in the US and not marketed elsewhere, thus it is unlikely to be affected by the proposed pricing changes. Botanix will review the executive order once it is available to assess any potential impact.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited is a dermatology company based in Philadelphia and Phoenix, specializing in the development of treatments for primary axillary hyperhidrosis. Its lead product, Sofdra, is the first FDA-approved new chemical entity for this condition, offering a novel and effective solution for patients with limited treatment options.
Average Trading Volume: 9,955,828
Technical Sentiment Signal: Buy
Current Market Cap: A$908.6M
For detailed information about BOT stock, go to TipRanks’ Stock Analysis page.